Summary
12.25 -0.04(-0.33%)08/30/2024
Certara Inc (CERT)
Certara Inc (CERT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.33 | -3.22 | -19.77 | -25.21 | -26.53 | -21.64 | 0.00 | -67.24 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 12.25 | |
| Open | 12.37 | |
| High | 12.54 | |
| Low | 12.05 | |
| Volume | 1,207,420 | |
| Change | -0.04 | |
| Change % | -0.33 | |
| Avg Volume (20 Days) | 826,861 | |
| Volume/Avg Volume (20 Days) Ratio | 1.46 | |
| 52 Week Range | 11.70 - 19.87 | |
| Price vs 52 Week High | -38.35% | |
| Price vs 52 Week Low | 4.70% | |
| Range | -4.63 | |
| Gap Up/Down | -0.16 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,971 | |
| EBIDTA | 2,468,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 43.40 | |
| Book Value | 6.1730 | |
| Earnings Per Share | -0.4000 | |
| EPS Estimate Current Quarter | 0.0600 | |
| EPS Estimate Next Quarter | 0.0600 | |
| EPS Estimate Current Year | 0.2400 | |
| EPS Estimate Next Year | 0.3600 | |
| Diluted EPS (TTM) | -0.4000 | |
| Revenues | ||
| Profit Marging | -0.2107 | |
| Operating Marging (TTM) | -0.1480 | |
| Return on asset (TTM) | -0.0209 | |
| Return on equity (TTM) | -0.0790 | |
| Revenue TTM | 275,399,008 | |
| Revenue per share TTM | 1.9010 | |
| Quarterly Revenue Growth (YOY) | 0.2260 | |
| Quarterly Earnings Growth (YOY) | -0.0950 | |
| Gross Profit (TTM) | 142,765,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 111.1111 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.5630 | |
| Revenue Enterprise Value | 15.6532 | |
| EBITDA Enterprise Value | 962.2976 | |
| Shares | ||
| Shares Outstanding | 159,660,000 | |
| Shares Float | 100,256,361 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 4.99 | |
| Institutions (%) | 78.61 | |
08/21 16:15 EST - globenewswire.com
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
08/15 16:15 EST - globenewswire.com
Certara Launches Phoenix™ Version 8.5 Drug Development Software
RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5.
Certara Launches Phoenix™ Version 8.5 Drug Development Software
RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5.
08/06 19:36 EST - seekingalpha.com
Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens David Windley - Jefferies Dan Clark - Leerink Partners Joe Vruwink - Baird Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Call.
Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens David Windley - Jefferies Dan Clark - Leerink Partners Joe Vruwink - Baird Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Call.
08/06 19:27 EST - zacks.com
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.12 per share a year ago.
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.12 per share a year ago.
08/06 16:15 EST - globenewswire.com
Certara Reports Second Quarter 2024 Financial Results
RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024.
Certara Reports Second Quarter 2024 Financial Results
RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024.
07/09 16:45 EST - globenewswire.com
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.
07/02 16:15 EST - globenewswire.com
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
06/17 08:00 EST - globenewswire.com
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.
05/29 16:15 EST - globenewswire.com
Certara to Participate in the Jefferies Global Healthcare Conference
RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.
Certara to Participate in the Jefferies Global Healthcare Conference
RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.
05/21 08:00 EST - globenewswire.com
Certara Appoints New Chief Human Resources Officer & General Counsel
RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel.
Certara Appoints New Chief Human Resources Officer & General Counsel
RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel.
05/20 04:43 EST - https://www.defenseworld.net
Swiss National Bank Reduces Stock Holdings in Certara, Inc. (NASDAQ:CERT)
Swiss National Bank cut its position in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,400 shares of the company’s stock after selling 43,200 shares during the period. Swiss National Bank owned approximately 0.14% of Certara worth $3,877,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its holdings in Certara by 31.2% in the third quarter. Commonwealth Equity Services LLC now owns 19,055 shares of the company’s stock valued at $277,000 after acquiring an additional 4,528 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Certara by 16.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,117 shares of the company’s stock valued at $351,000 after purchasing an additional 3,482 shares during the last quarter. M&T Bank Corp lifted its stake in shares of Certara by 19.2% in the 3rd quarter. M&T Bank Corp now owns 141,368 shares of the company’s stock valued at $2,055,000 after purchasing an additional 22,759 shares during the last quarter. EFG Asset Management North America Corp. purchased a new position in shares of Certara during the 3rd quarter worth $1,570,000. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of Certara during the 3rd quarter worth about $941,000. 73.96% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling at Certara In other news, SVP Richard M. Traynor sold 3,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the transaction, the senior vice president now owns 173,524 shares in the company, valued at approximately $3,123,432. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, SVP Richard M. Traynor sold 3,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at $3,123,432. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Patrick F. Smith sold 14,427 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $844,033.35. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders. Certara Price Performance Shares of CERT opened at $16.08 on Monday. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -41.23, a PEG ratio of 1.61 and a beta of 1.61. The firm’s fifty day simple moving average is $17.41 and its 200-day simple moving average is $16.66. Certara, Inc. has a twelve month low of $11.81 and a twelve month high of $22.65. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27. Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The business had revenue of $88.01 million for the quarter, compared to analysts’ expectations of $86.80 million. Equities analysts forecast that Certara, Inc. will post 0.29 EPS for the current fiscal year. Analyst Ratings Changes Several research analysts have weighed in on the stock. Barclays increased their target price on shares of Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. UBS Group lifted their target price on shares of Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, March 1st. Leerink Partnrs restated a “market perform” rating on shares of Certara in a research note on Monday, February 26th. Jefferies Financial Group lifted their price objective on Certara from $14.00 to $15.50 and gave the company a “hold” rating in a research note on Friday, March 1st. Finally, SVB Leerink started coverage on Certara in a research note on Monday, February 26th. They set a “market perform” rating and a $19.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Certara currently has a consensus rating of “Hold” and an average price target of $20.06. View Our Latest Research Report on CERT Certara Company Profile (Free Report) Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Swiss National Bank Reduces Stock Holdings in Certara, Inc. (NASDAQ:CERT)
Swiss National Bank cut its position in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,400 shares of the company’s stock after selling 43,200 shares during the period. Swiss National Bank owned approximately 0.14% of Certara worth $3,877,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its holdings in Certara by 31.2% in the third quarter. Commonwealth Equity Services LLC now owns 19,055 shares of the company’s stock valued at $277,000 after acquiring an additional 4,528 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Certara by 16.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,117 shares of the company’s stock valued at $351,000 after purchasing an additional 3,482 shares during the last quarter. M&T Bank Corp lifted its stake in shares of Certara by 19.2% in the 3rd quarter. M&T Bank Corp now owns 141,368 shares of the company’s stock valued at $2,055,000 after purchasing an additional 22,759 shares during the last quarter. EFG Asset Management North America Corp. purchased a new position in shares of Certara during the 3rd quarter worth $1,570,000. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of Certara during the 3rd quarter worth about $941,000. 73.96% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling at Certara In other news, SVP Richard M. Traynor sold 3,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the transaction, the senior vice president now owns 173,524 shares in the company, valued at approximately $3,123,432. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, SVP Richard M. Traynor sold 3,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at $3,123,432. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Patrick F. Smith sold 14,427 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $844,033.35. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders. Certara Price Performance Shares of CERT opened at $16.08 on Monday. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -41.23, a PEG ratio of 1.61 and a beta of 1.61. The firm’s fifty day simple moving average is $17.41 and its 200-day simple moving average is $16.66. Certara, Inc. has a twelve month low of $11.81 and a twelve month high of $22.65. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27. Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The business had revenue of $88.01 million for the quarter, compared to analysts’ expectations of $86.80 million. Equities analysts forecast that Certara, Inc. will post 0.29 EPS for the current fiscal year. Analyst Ratings Changes Several research analysts have weighed in on the stock. Barclays increased their target price on shares of Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. UBS Group lifted their target price on shares of Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, March 1st. Leerink Partnrs restated a “market perform” rating on shares of Certara in a research note on Monday, February 26th. Jefferies Financial Group lifted their price objective on Certara from $14.00 to $15.50 and gave the company a “hold” rating in a research note on Friday, March 1st. Finally, SVB Leerink started coverage on Certara in a research note on Monday, February 26th. They set a “market perform” rating and a $19.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Certara currently has a consensus rating of “Hold” and an average price target of $20.06. View Our Latest Research Report on CERT Certara Company Profile (Free Report) Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
05/08 03:56 EST - seekingalpha.com
Certara, Inc. (CERT) Q1 2024 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants David Windley - Jefferies Luke Sergott - Barclays Michael Ryskin - Bank of America Max Smock - William Blair Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara First Quarter 2024 Earnings Conference Call.
Certara, Inc. (CERT) Q1 2024 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants David Windley - Jefferies Luke Sergott - Barclays Michael Ryskin - Bank of America Max Smock - William Blair Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara First Quarter 2024 Earnings Conference Call.
05/07 19:41 EST - zacks.com
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago.
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago.
05/07 16:15 EST - globenewswire.com
Certara Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024.
Certara Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024.
04/16 08:00 EST - globenewswire.com
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.
04/09 16:15 EST - globenewswire.com
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
02/29 21:33 EST - seekingalpha.com
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
02/29 19:06 EST - zacks.com
Certara, Inc. (CERT) Lags Q4 Earnings Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
Certara, Inc. (CERT) Lags Q4 Earnings Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
02/29 16:10 EST - globenewswire.com
Certara Reports Fourth Quarter 2023 Financial Results
PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023.
Certara Reports Fourth Quarter 2023 Financial Results
PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023.
02/01 16:30 EST - globenewswire.com
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.